Conjupro Biotherapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding, Subsidiary
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.conjuprobio.com
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05948865
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Registration Number
- NCT05043987
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT04931823
- Locations
- 🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
Dose Escalation and Expansion Study of CPO107 for Patients with Advanced CD20-positive Non-Hodgkins Lymphoma
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04853329
- Locations
- 🇺🇸
Novant Health, Charlotte, North Carolina, United States
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
- Conditions
- Peripheral NeuropathyBreast Cancer
- Interventions
- Drug: PlaceboDrug: NBP Softgel Capsules
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Registration Number
- NCT04675450
Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects
- Conditions
- Hypertension
- Interventions
- Drug: Levamlodipine, Amlodipine
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03657550
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Registration Number
- NCT03567694
- Locations
- 🇺🇸
CNS Network, Long Beach, California, United States
PLM60 for Peripheral T Cell Lymphoma (PTCL)
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Registration Number
- NCT03553914
- Locations
- 🇺🇸
Gabrial Cancer Center, Canton, Ohio, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States